WO1999059970A1 - Method for making substituted indoles - Google Patents

Method for making substituted indoles Download PDF

Info

Publication number
WO1999059970A1
WO1999059970A1 PCT/US1999/010415 US9910415W WO9959970A1 WO 1999059970 A1 WO1999059970 A1 WO 1999059970A1 US 9910415 W US9910415 W US 9910415W WO 9959970 A1 WO9959970 A1 WO 9959970A1
Authority
WO
WIPO (PCT)
Prior art keywords
substituted
structural formula
unsubstituted
group
represented
Prior art date
Application number
PCT/US1999/010415
Other languages
French (fr)
Inventor
Robert Stevenson
Milind P. Sant
Reem Haider
Ahmed Hilmy
Emile Al-Farham
Original Assignee
Pharm-Eco Laboratories, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharm-Eco Laboratories, Inc. filed Critical Pharm-Eco Laboratories, Inc.
Priority to AU39845/99A priority Critical patent/AU3984599A/en
Priority to JP2000549589A priority patent/JP2002515485A/en
Priority to CA002332766A priority patent/CA2332766A1/en
Priority to EP99922971A priority patent/EP1077939A1/en
Publication of WO1999059970A1 publication Critical patent/WO1999059970A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16Tryptamines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12Radicals substituted by oxygen atoms

Definitions

  • Melatonin (Structural Formula I) is a hormone that is synthesized in the pineal gland and in the eye and is involved in the regulation of circadian and circannual rhythms .
  • melatonin levels of melatonin are high at night because exposure to light inhibits its synthesis. In addition, melatonin has been shown to lower the body temperature and to have a sedative effect. Melatonin, and compounds structurally related to melatonin (e.g., substituted indoles) , are useful in treating a number of human disorders. For example, sleep disorders, particularly in the elderly, have been shown to respond to treatment with melatonin (Waldhauser, et al . , Psyche-pharmacology, (1990), 100:222; Vollrath, et al .
  • melatonin has been useful in treating chronobiologic conditions, such as jet lag or work shift changes (Short, et al . , U.S. Patent Nos. 4,600,723 and 4,665,086; Lewy, et al . , U.S. Patent No. 5,242,941) .
  • Neurodegenerative diseases such as Parkinson's disease and Alzheimer's disease, may also benefit from treatment with melatonin or melatonin derivatives, since levels of melatonin decrease with age (Sack, et al . , Pineal Res . , (1986), 4:379; Waldhauser, et al . , J. Clin . Metab . , (1988), f5f5:645; Van Coevorden, et al . , Am. J. Physiolog. , (1991), 2f50:E651) .
  • Patients with Alzheimer's disease in particular exhibit circadian rhythm disruptions, and therefore, may benefit from these compounds (Kandel, et al . , Principles of Neuroscience, 3 rd Edi tion (1991), Appleton & Lange, Norwalk, Connecticut, p. 808) .
  • Melatonin has also been shown to have analgesic (Sugden, J “ . Pharmacol . Exp . Ther. , (1983), 227:587) and antiseizure activity (Brailowsky, Electroencephalo . Clin . Neurophysiol . , (1976), 41:314; Golombek, et al . , Eur . J. Pharmacol . , (1992), 210:253). Therefore, compounds related to melatonin may be effective in treating conditions such as migraine headache and epilepsy. Psychiatric disorders, such as seasonal affective disorder, anxiety disorders, depression, schizophrenia, and mania, may respond to treatment with melatonin related compounds (Dubocovich, U.S.
  • Patent 5,093,352 Miles, et al . , Biol . Psychia try, (1988), 23:405; Sandyk, et al . , Schizophr. Bull . , (1990), 16 " :653) .
  • manic or depressed patients often exhibit sleep disorders.
  • melatonin secretion has been shown to be abnormal in humans suffering from anxiety disorder (Mcintyre, et al . , Am . J. Psychiat . , (1990), 147:462).
  • Compounds related to melatonin may also be useful in treating precocious puberty, premenstrual syndrome or as fertility or contraceptive agents because production of melatonin is known to change at puberty.
  • melatonin regulates fertility, hibernation and puberty (Fevre, et al . , J " . Clin .
  • the substituted, fused polycyclic nitrogen-containing heteroaromatic compound is represented by Structural Formula (II) :
  • R 1 is -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group.
  • R 1 is -H or a C1-C5 alkyl group.
  • R 2 is a substituted or unsubstituted 2-hydroxy-l -ethyl group .
  • Ring A is a substituted or unsubstituted aryl group.
  • Ring B is substituted or unsubstituted at position two.
  • a numbering system for the ring atoms of Ring B is provided in Structural Formula (II) .
  • the method comprises the step of reacting a 2,3- dihydrofuran with a substituted or unsubstituted aryl hydrazine represented by Structural Formula (III) or with a salt derived from a compound having a formula represented by Structural Formula (III) :
  • R 1 and ring A are as described above for Structural Formula (II) .
  • the fused polycyclic nitrogen- containing heteroaromatic compound is represented by structural formula (IV) :
  • R 1 and ring A are as described for Structural Formula (ID .
  • R 3 , R 4 , R 4' , R 5 , and R 5' are each, independently, -H, aliphatic groups, substituted aliphatic groups, aryl group, substituted aryl groups, halogens, halogenated aliphatic groups, nitro, nitrile, -C(0)NHR, -C(0)NRR, -NHC(0)R, -NRC(0)R, -OR, -SR, -S(0)R, -S(0) 2 R.
  • R is an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group.
  • the method of preparing a compound represented by Structural Formula (IV) comprises the step of reacting a substituted or unsubstituted aryl hydrazine represented by Structural Formula (III) or a salt derived from a substituted or unsubstituted aryl hydrazine represented by Structural Formula (III) with a compound represented by Structural Formula (V) :
  • R 3 , R 4 , R 4' , R 5 , and R 5' are as described for Structural Formula (IV) .
  • the method described above for preparing substituted, fused polycyclic nitrogen-containing heteroaromatic compounds provides access to a variety of compounds that are structurally related to melatonin, and therefore, facilitates the development of drugs for the treatment of conditions related to abnormalities in melatonin production.
  • Fig. 1 is a reaction scheme showing the reaction of phenylhydrazine hydrochloride with a 2 , 3 -dihydrofuran substituted at positions two, four or five with R 3 , R 4 , R 4 ' , R 5 , and R 5 ' .
  • Fig. 2 is a reaction scheme showing the conversion of 4-isopropylphenylhydrazine and 2 , 3 -dihydrofuran to 5- isopropyl-3- [2 (N-pyrrolidino) ethyl] -lH-indole .
  • the method of preparing substituted, fused, polycyclic nitrogen-containing aromatic compounds represented by Structural Formula (II) comprises the step of reacting substituted or unsubstituted 2 , 3-dihydrofuran with a substituted or unsubstituted aryl hydrazine represented by Structural Formula (III) or a salt derived from a substituted or unsubstituted aryl hydrazine represented by Structural Formula (III) .
  • a method of preparing a fused polycyclic nitrogen-containing heteroaromatic compound represented by Structural Formula (IV) is disclosed.
  • the method comprises the step of reacting a substituted or unsubstituted aryl hydrazine represented by Structural Formula (III) or a salt derived from a substituted or unsubstituted aryl hydrazine represented by Structural Formula (III) with a compound represented by Structural Formula (V) .
  • the 2 , 3-dihydrofuran is unsubstituted or substituted.
  • a substituted 2 , 3-dihydrofuran is a 2,3- dihydrofuran substituted at position two, four and/or five with one or more substitutents .
  • the reaction of phenylhydrazine hydrochloride with a 2 , 3-dihydrofuran substituted at positions two, four or five with R 3 , R 4 , R 4 ' , R 5 and R 5 ' is shown schematically in Fig. 1.
  • the aryl hydrazine represented by Structural Formula (III) or derived salt is reacted with an unsubstituted 2 , 3 -dihydrofuran.
  • the fused polycyclic nitrogen-containing heteroaromatic compound formed by this reaction is represented by Structural Formula (VI) :
  • Ring A and R 1 are as described above for Structural Formula (II) .
  • a substituted or unsubstituted 2 , 3-dihydrofuran is reacted with a phenyl hydrazine represented by Structural Formula (VII) or with a salt derived from a compound represented by Structural formula (VII) :
  • the fused polycyclic nitrogen-containing heteroaromatic compound formed by this reaction is a substituted indole represented by Structural Formula (VIII) :
  • Structural Formulas (VII) and (VIII) ring A is substituted or unsubstituted, ring B is substituted or unsubstituted at position 2, and R 1 and R 2 are as described for Structural Formula (II) .
  • an unsubstituted 2,3- dihydrofuran is reacted with a phenyl hydrazine represented by Structural Formula (VII) or with a salt derived from a compound represented by Structural Formula (VII) .
  • the substituted indole formed by this reaction is represented by Structural Formula (IX) :
  • rings A is substituted or unsubstituted, and R 1 is as described for Structural Formula (II) .
  • R 1 is -H or -CH 3 .
  • the reaction is generally carried out in an ethereal solvent which is miscible in water, for example, tetrahydrofuran (THF) , glyme, diglyme or 1,4-dioxane. THF is a preferred solvent. A sufficient amount of water or other polar solvent is added to dissolve the hydrazine salt.
  • THF tetrahydrofuran
  • Suitable polar solvents include alcohols (e.g., methanol, ethanol and isopropanol) , nitroalkanes, acetonitrile, dimethyl sulfoxide, dimethylformamide and hexamethylphosphoramide .
  • the 2 , 3-dihydrofuran and the aryl hydrazine or aryl hydrazine salt are present generally in about equimolar amounts. However, one reagent can be present in a large excess relative to the other, for example, a two to three fold excess relative to the other. Preferably, the 2,3- dihydrofuran is present in a molar excess relative to the hydrazine salt up to about 50%, more preferably about 10%.
  • the 2 , 3-dihydrofuran and aryl hydrazine or aryl hydrazine salt are present at concentrations ranging from 0.25 M to about 5.0 M, preferably from about 0.25 M to about 0.75 M.
  • the reagents can be mixed in any order.
  • the 2 , 3-dihydrofuran is generally added to a mixture of the aryl hydrazine or aryl hydrazine salt in water and an ethereal solvent.
  • the reagents are typically mixed slowly, e.g., dropwise.
  • the optimal reaction time and temperature depends on factors such as the solvent and concentration, which the skilled artisan will be able to adjust so as to maximize the yield of product.
  • the reaction is maintained at temperatures ranging from room temperature to reflux until completion. Reaction completion can be monitored by usual methods, for example, by gas chromatography or thin layer chromatography.
  • the substituted, fused, polycyclic nitrogen-containing aromatic compounds represented by Structural Formulas (II), (IV) , (VI) , (VIII) , and (IX) are obtained as the free base which can be converted to a salt by recrystallization with an acid such as succinic acid. Physiologically acceptable salts are preferred.
  • the salt can be converted back to the free base by treating with a basic solution, such as an aqueous sodium bicarbonate solution, followed by extraction of the substituted, fused, polycyclic nitrogen-containing aromatic compounds with an organic solvent.
  • the alcohol group of the compounds represented by Structural Formulas (II), (IV), (VI), (VIII) and (IX) can be further converted into other useful functionalities by reacting the alcohol with an activating agent which converts the alcohol into a suitable leaving group.
  • Suitable activating agents include thionyl halides, sulfonyl halides, P0C1 3 , PC1 5 , and PC1 3 .
  • the alcohol can be converted to a halide by reacting it with thionyl halide.
  • the alcohol can be converted to a sulfonate ester, such as a mesylate, by reacting it with a sulfonyl chloride, such as methanesulfonyl chloride.
  • a suitable nucleophilic compound examples include amines, RO " and RS " .
  • R is an alkyl group, a substituted alcohol group, an aryl group and a substituted aryl group.
  • Amines are preferred nucleophilic compounds.
  • Pyrrolidine is a particularly preferred nucleophilic compound.
  • aliphatic groups include straight chained, branched C1-C20 hydrocarbons or cyclic
  • the aliphatic group is a C1-C10 alkyl group.
  • Aryl groups include carbocyclic aromatic groups such as phenyl, naphthyl, and anthracyl, and heteroaryl groups such as thienyl, furanyl , thiazolyl and oxazolyl .
  • Aryl groups also include fused polycyclic aromatic ring systems in which a carbocyclic aromatic ring or heteroaryl ring is fused to one or more other heteroaryl rings . Examples include benzothienyl , benzofuranyl , benzothiazolyl and benzooxazolyl .
  • Suitable substituents for a 2 , 3 -dihydrofuran and for an aryl group, aliphatic group, and the 2-hydroxy-l-ethyl group in Structural Formulas (II) -(IX) are those which are compatible with the reaction, i.e., do not significantly reduce the yield of the reaction and do not cause a significant amount of side reactions.
  • a 2 , 3 -dihydrofuran, an aryl group, an aliphatic group, and a 2-hydroxy-l -ethyl group can have more than one substituent.
  • Suitable substituents generally include groups which are not strongly basic and or highly electrophilic .
  • substituents include aliphatic groups, a substituted aliphatic group, aryl groups, a substituted aryl, halogens, halogenated alkyl groups (e.g., trihalomethyl) , nitro, nitrile, -C(0)NHR, -C(0)NRR,
  • each R is independently an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group.
  • Alipatic and aryl substituents can be further substituted at one or more positions with an aliphatic group, an aryl group, a halogen, a halogenated alkyl group (e.g., trihalomethyl), nitro, nitrile, -C(0)NHR, -C(0)NRR, -NHC(0)R, -NRC(0)R, -OR, -SR, -S(0)R, or -S(0) 2 R.
  • an aliphatic group an aryl group
  • a halogen e.g., trihalomethyl
  • nitro, nitrile, -C(0)NHR, -C(0)NRR, -NHC(0)R, -NRC(0)R, -OR, -SR, -S(0)R, or -S(0) 2 R e.g., trihalomethyl
  • Salts derived from an aryl hydrazine represented by Structural Formulas (III) and (VII) are prepared by reacting the aryl hydrazine with a mineral acid.
  • suitable salts include the hydrochloride salt, the hydrobromide salt, the hydroiodide salt, the salts of H 2 S0 4 , HN0 3 , H 3 P0 4 and the like.
  • Example 3 Crystallization of the 5-Isopropyl-3- [2 (N- pyrrolidino) ethyl) ] -1-H-indole Succinic Acid Salt
  • the crude material from Example 2 (111 g, 432 mmol) was dissolved in hot methanol (600 mL) and added to a hot solution of succinic acid (51.1 g, 432 mmol) in MeOH (250 mL) . After stirring for 5 hours, the white solid formed was filtered washed with ethanol to yield 111 g (70%) of 98% pure product.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Indole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is a method of preparing a compound represented by structural formula (II), and physiological salts thereof. R1 is -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. R2 is a substituted or unsubstituted 2-hydroxy-1-ethyl group. Ring A is a substituted or unsubstituted aryl group. Ring B is substituted or unsubstituted at position two. The method comprises reacting a substituted or unsubstituted aryl hydrazine or salt derived from a substituted or unsubstituted aryl hydrazine with a compound represented by structural formula (III).

Description

METHOD FOR MAKING SUBSTITUTED INDOLES
RELATED APPLICATION
This application claims the benefit of U.S. Provisional Application No. 60/085,639, filed on May 15, 1998, entitled "Practical Method for Making Substituted Indoles," the entire teachings of which are incorporated herein by reference.
BACKGROUND OF THE INVENTION
Melatonin (Structural Formula I) is a hormone that is synthesized in the pineal gland and in the eye and is involved in the regulation of circadian and circannual rhythms .
Figure imgf000003_0001
Levels of melatonin are high at night because exposure to light inhibits its synthesis. In addition, melatonin has been shown to lower the body temperature and to have a sedative effect. Melatonin, and compounds structurally related to melatonin (e.g., substituted indoles) , are useful in treating a number of human disorders. For example, sleep disorders, particularly in the elderly, have been shown to respond to treatment with melatonin (Waldhauser, et al . , Psyche-pharmacology, (1990), 100:222; Vollrath, et al .
Bioscience, (1981), 25:327; Dollins, et al . , Proc . Natl . Acad . Sci . , (1994), 55:1824). In addition, melatonin has been useful in treating chronobiologic conditions, such as jet lag or work shift changes (Short, et al . , U.S. Patent Nos. 4,600,723 and 4,665,086; Lewy, et al . , U.S. Patent No. 5,242,941) .
Neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, may also benefit from treatment with melatonin or melatonin derivatives, since levels of melatonin decrease with age (Sack, et al . , Pineal Res . , (1986), 4:379; Waldhauser, et al . , J. Clin . Metab . , (1988), f5f5:645; Van Coevorden, et al . , Am. J. Physiolog. , (1991), 2f50:E651) . Patients with Alzheimer's disease in particular exhibit circadian rhythm disruptions, and therefore, may benefit from these compounds (Kandel, et al . , Principles of Neuroscience, 3rd Edi tion (1991), Appleton & Lange, Norwalk, Connecticut, p. 808) .
Melatonin has also been shown to have analgesic (Sugden, J". Pharmacol . Exp . Ther. , (1983), 227:587) and antiseizure activity (Brailowsky, Electroencephalo . Clin . Neurophysiol . , (1976), 41:314; Golombek, et al . , Eur . J. Pharmacol . , (1992), 210:253). Therefore, compounds related to melatonin may be effective in treating conditions such as migraine headache and epilepsy. Psychiatric disorders, such as seasonal affective disorder, anxiety disorders, depression, schizophrenia, and mania, may respond to treatment with melatonin related compounds (Dubocovich, U.S. Patent 5,093,352; Miles, et al . , Biol . Psychia try, (1988), 23:405; Sandyk, et al . , Schizophr. Bull . , (1990), 16":653) . For example, manic or depressed patients often exhibit sleep disorders. In addition, melatonin secretion has been shown to be abnormal in humans suffering from anxiety disorder (Mcintyre, et al . , Am . J. Psychiat . , (1990), 147:462). Compounds related to melatonin may also be useful in treating precocious puberty, premenstrual syndrome or as fertility or contraceptive agents because production of melatonin is known to change at puberty. In addition, in seasonal breeding species melatonin regulates fertility, hibernation and puberty (Fevre, et al . , J". Clin .
Endocrinol . Me tab . , (1978), 47:1383; Parrey, et al . , Am . J. Psychiatry, (1987), 144:762; Waldhauser, et al . , J. Clin . Endocrinol . Me tab . , (1991), 73:793; Bispink, et al . , J. Pineal Res . , (1990), 8:97; Cagnacci, et al . , J. Clin . Endocrinol . Metab . , (1991), 73:210; Voordouw, et al . , J. Clin . Endocrinol . Metab . , (1992), 73:107; Fraschini, et al . , 5,272,141; Cohen, et al . , U.S. Pat. Nos . 4,855,305 and 4,945,103) . Therefore, compounds related to melatonin may have applications to animal husbandry. As described above, abnormalities in melatonin production have been implicated in a number of human and animal disorders. Compounds which are structurally related to melatonin are expected to have many therapeutic applications because they have the potential to mimic the activity of melatonin or block melatonin receptors. A versatile synthetic route that would allow for a variety of substitution patterns would facilitate the production of melatonin related compounds. Melatonin related compounds and their uses are more fully described in U.S. Patent Nos. 5,403,851 and 5,580,878, the entire teachings of which are hereby incorporated by reference.
SUMMARY OF THE INVENTION
Disclosed herein is a method of preparing substituted, fused polycyclic nitrogen-containing heteroaromatic compounds, including substituted indoles and physiologically acceptable salts thereof. The substituted, fused polycyclic nitrogen-containing heteroaromatic compound is represented by Structural Formula (II) :
Figure imgf000006_0001
R1 is -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. For example, R1 is -H or a C1-C5 alkyl group.
R2 is a substituted or unsubstituted 2-hydroxy-l -ethyl group .
Ring A is a substituted or unsubstituted aryl group.
Ring B is substituted or unsubstituted at position two. A numbering system for the ring atoms of Ring B is provided in Structural Formula (II) .
The method comprises the step of reacting a 2,3- dihydrofuran with a substituted or unsubstituted aryl hydrazine represented by Structural Formula (III) or with a salt derived from a compound having a formula represented by Structural Formula (III) :
Figure imgf000007_0001
R1 and ring A are as described above for Structural Formula (II) .
In another embodiment, the fused polycyclic nitrogen- containing heteroaromatic compound is represented by structural formula (IV) :
Figure imgf000008_0001
R1 and ring A are as described for Structural Formula (ID .
R3, R4, R4', R5, and R5' are each, independently, -H, aliphatic groups, substituted aliphatic groups, aryl group, substituted aryl groups, halogens, halogenated aliphatic groups, nitro, nitrile, -C(0)NHR, -C(0)NRR, -NHC(0)R, -NRC(0)R, -OR, -SR, -S(0)R, -S(0)2R.
R is an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group.
The method of preparing a compound represented by Structural Formula (IV) comprises the step of reacting a substituted or unsubstituted aryl hydrazine represented by Structural Formula (III) or a salt derived from a substituted or unsubstituted aryl hydrazine represented by Structural Formula (III) with a compound represented by Structural Formula (V) :
Figure imgf000009_0001
R3, R4, R4', R5, and R5' are as described for Structural Formula (IV) .
The method described above for preparing substituted, fused polycyclic nitrogen-containing heteroaromatic compounds provides access to a variety of compounds that are structurally related to melatonin, and therefore, facilitates the development of drugs for the treatment of conditions related to abnormalities in melatonin production.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is a reaction scheme showing the reaction of phenylhydrazine hydrochloride with a 2 , 3 -dihydrofuran substituted at positions two, four or five with R3 , R4, R4 ' , R5, and R5 ' .
Fig. 2 is a reaction scheme showing the conversion of 4-isopropylphenylhydrazine and 2 , 3 -dihydrofuran to 5- isopropyl-3- [2 (N-pyrrolidino) ethyl] -lH-indole .
DETAILED DESCRIPTION OF THE INVENTION The features and other details of the method on the invention will now be more particularly described and pointed out in the claims. It will be understood that the particular embodiments of the invention are shown by way of illustration and not as limitations of the invention. The principle features of this invention can be employed in various embodiments without departing from the scope of the invention. All parts and percentages are by weight unless otherwise specified.
The method of preparing substituted, fused, polycyclic nitrogen-containing aromatic compounds represented by Structural Formula (II) comprises the step of reacting substituted or unsubstituted 2 , 3-dihydrofuran with a substituted or unsubstituted aryl hydrazine represented by Structural Formula (III) or a salt derived from a substituted or unsubstituted aryl hydrazine represented by Structural Formula (III) . In another embodiment, a method of preparing a fused polycyclic nitrogen-containing heteroaromatic compound represented by Structural Formula (IV) is disclosed. The method comprises the step of reacting a substituted or unsubstituted aryl hydrazine represented by Structural Formula (III) or a salt derived from a substituted or unsubstituted aryl hydrazine represented by Structural Formula (III) with a compound represented by Structural Formula (V) .
The 2 , 3-dihydrofuran is unsubstituted or substituted. As used herein, a substituted 2 , 3-dihydrofuran is a 2,3- dihydrofuran substituted at position two, four and/or five with one or more substitutents . For example, the reaction of phenylhydrazine hydrochloride with a 2 , 3-dihydrofuran substituted at positions two, four or five with R3, R4, R4 ' , R5 and R5 ' is shown schematically in Fig. 1. In a preferred embodiment, the aryl hydrazine represented by Structural Formula (III) or derived salt is reacted with an unsubstituted 2 , 3 -dihydrofuran. The fused polycyclic nitrogen-containing heteroaromatic compound formed by this reaction is represented by Structural Formula (VI) :
Figure imgf000011_0001
Ring A and R1 are as described above for Structural Formula (II) . In another preferred embodiment, a substituted or unsubstituted 2 , 3-dihydrofuran is reacted with a phenyl hydrazine represented by Structural Formula (VII) or with a salt derived from a compound represented by Structural formula (VII) :
Figure imgf000011_0002
The fused polycyclic nitrogen-containing heteroaromatic compound formed by this reaction is a substituted indole represented by Structural Formula (VIII) :
Figure imgf000012_0001
In Structural Formulas (VII) and (VIII) , ring A is substituted or unsubstituted, ring B is substituted or unsubstituted at position 2, and R1 and R2 are as described for Structural Formula (II) . In a more specific embodiment, an unsubstituted 2,3- dihydrofuran is reacted with a phenyl hydrazine represented by Structural Formula (VII) or with a salt derived from a compound represented by Structural Formula (VII) . The substituted indole formed by this reaction is represented by Structural Formula (IX) :
Figure imgf000013_0001
In Structural Formula (IX), rings A is substituted or unsubstituted, and R1 is as described for Structural Formula (II) . In a preferred embodiment, R1 is -H or -CH3. The reaction is generally carried out in an ethereal solvent which is miscible in water, for example, tetrahydrofuran (THF) , glyme, diglyme or 1,4-dioxane. THF is a preferred solvent. A sufficient amount of water or other polar solvent is added to dissolve the hydrazine salt. Suitable polar solvents include alcohols (e.g., methanol, ethanol and isopropanol) , nitroalkanes, acetonitrile, dimethyl sulfoxide, dimethylformamide and hexamethylphosphoramide .
The 2 , 3-dihydrofuran and the aryl hydrazine or aryl hydrazine salt are present generally in about equimolar amounts. However, one reagent can be present in a large excess relative to the other, for example, a two to three fold excess relative to the other. Preferably, the 2,3- dihydrofuran is present in a molar excess relative to the hydrazine salt up to about 50%, more preferably about 10%. The 2 , 3-dihydrofuran and aryl hydrazine or aryl hydrazine salt are present at concentrations ranging from 0.25 M to about 5.0 M, preferably from about 0.25 M to about 0.75 M. The reagents can be mixed in any order. However, the 2 , 3-dihydrofuran is generally added to a mixture of the aryl hydrazine or aryl hydrazine salt in water and an ethereal solvent. Because the reaction is exothermic, the reagents are typically mixed slowly, e.g., dropwise. The optimal reaction time and temperature depends on factors such as the solvent and concentration, which the skilled artisan will be able to adjust so as to maximize the yield of product. Generally, after mixing, the reaction is maintained at temperatures ranging from room temperature to reflux until completion. Reaction completion can be monitored by usual methods, for example, by gas chromatography or thin layer chromatography.
The substituted, fused, polycyclic nitrogen-containing aromatic compounds represented by Structural Formulas (II), (IV) , (VI) , (VIII) , and (IX) are obtained as the free base which can be converted to a salt by recrystallization with an acid such as succinic acid. Physiologically acceptable salts are preferred. The salt can be converted back to the free base by treating with a basic solution, such as an aqueous sodium bicarbonate solution, followed by extraction of the substituted, fused, polycyclic nitrogen-containing aromatic compounds with an organic solvent.
The alcohol group of the compounds represented by Structural Formulas (II), (IV), (VI), (VIII) and (IX) can be further converted into other useful functionalities by reacting the alcohol with an activating agent which converts the alcohol into a suitable leaving group. Suitable activating agents include thionyl halides, sulfonyl halides, P0C13, PC15, and PC13. For example, the alcohol can be converted to a halide by reacting it with thionyl halide. Alternatively, the alcohol can be converted to a sulfonate ester, such as a mesylate, by reacting it with a sulfonyl chloride, such as methanesulfonyl chloride. The leaving group can then be displaced by a suitable nucleophilic compound. Examples of nucleophilic compounds include amines, RO" and RS" . R is an alkyl group, a substituted alcohol group, an aryl group and a substituted aryl group. Amines are preferred nucleophilic compounds. Pyrrolidine is a particularly preferred nucleophilic compound.
The term "aliphatic groups," as used herein, include straight chained, branched C1-C20 hydrocarbons or cyclic
C3-C20 hydrocarbons which are completely saturated or which contain one or more units of unsaturation. In one example, the aliphatic group is a C1-C10 alkyl group.
Aryl groups include carbocyclic aromatic groups such as phenyl, naphthyl, and anthracyl, and heteroaryl groups such as thienyl, furanyl , thiazolyl and oxazolyl . Aryl groups also include fused polycyclic aromatic ring systems in which a carbocyclic aromatic ring or heteroaryl ring is fused to one or more other heteroaryl rings . Examples include benzothienyl , benzofuranyl , benzothiazolyl and benzooxazolyl .
Suitable substituents for a 2 , 3 -dihydrofuran and for an aryl group, aliphatic group, and the 2-hydroxy-l-ethyl group in Structural Formulas (II) -(IX) are those which are compatible with the reaction, i.e., do not significantly reduce the yield of the reaction and do not cause a significant amount of side reactions. A 2 , 3 -dihydrofuran, an aryl group, an aliphatic group, and a 2-hydroxy-l -ethyl group can have more than one substituent. Suitable substituents generally include groups which are not strongly basic and or highly electrophilic . Examples of suitable substituents include aliphatic groups, a substituted aliphatic group, aryl groups, a substituted aryl, halogens, halogenated alkyl groups (e.g., trihalomethyl) , nitro, nitrile, -C(0)NHR, -C(0)NRR,
-NHC(0)R, -NRC(0)R, -OR, -SR, -S(0)R, or -S(0)2R, wherein each R is independently an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group. Alipatic and aryl substituents can be further substituted at one or more positions with an aliphatic group, an aryl group, a halogen, a halogenated alkyl group (e.g., trihalomethyl), nitro, nitrile, -C(0)NHR, -C(0)NRR, -NHC(0)R, -NRC(0)R, -OR, -SR, -S(0)R, or -S(0)2R.
Although strongly basic groups such as amines and highly electrophilic groups such as acid chlorides, ketones, aldehydes and esters are not generally compatible with the reaction used in the method of the present invention, these functional groups can be present if they are first converted to a suitable protected form. For example, an aldehyde or a ketone can be protected by forming an acetal or a ketal , respectively, and an a ine group can be protected by forming an amide. The protecting group can then be removed after the reaction. Protecting groups are well known in the art and are described in, for example, Greene and Wuts, "Protective Groups in Organic Synthesis", John Wiley & Sons (1991), the entire teachings of which are incorporated into this application by reference. The skilled artisan can select, using no more than routine experimentation, suitable protecting groups for use in the disclosed synthesis as well as conditions for applying and removing the protecting groups.
Salts derived from an aryl hydrazine represented by Structural Formulas (III) and (VII) are prepared by reacting the aryl hydrazine with a mineral acid. Examples of suitable salts include the hydrochloride salt, the hydrobromide salt, the hydroiodide salt, the salts of H2S04, HN03, H3P04 and the like.
The invention is illustrated by the following examples which are not intended to be limiting in any way.
EXAMPLES
Example 1 Preparation of 5-Isopropyltryptophol (Fig.
2 , Compound (3 ) ) : A solution of 2 , 3-dihydrofuran (540 mL) in THF (1.2 L) was added slowly to a solution of 4- isopropylphenylhydrazine hydrochloride (1.2 kg, 6.43 mol) in 9.6 L of THF and 600 mL of H20 through an addition funnel at room temperature. At the end of the addition a solid was formed and temperature reached 60°C. The reaction mixture was refluxed for 5 hours and monitored by TLC and HPLC . After cooling, solvent was removed under reduced pressure. The residue was treated with H20 and extracted with EtOAc (2 x 7L) . The organic layers were combined, washed with water (3 L) , dried over anhydrous sodium sulfate and evaporated to give a residual dark brown material which was purified by silica-gel flash column chromatography and elution with 30% EtOAc/Hexane to give
570 g (45%) of 90% pure product.
Example 2 Preparation of 5-Isopropyl-3- [2 (N- pyrrolidino) ethyl] -lH-indole (Fig. 2, Compound (5) ) : Methanesulfonyl chloride (60.9 g., 532 mmol) was added slowly to a mixture of 5-isopropyltryptophol (90.0 g, 443 mmol) and triethylamine (67.2 g, 665 mmol) in methylene chloride (1500 mL) at 0°C. The reaction mixture was stirred for 1.5 hours. Reaction progress was checked by TLC (silica-gel, 50% EtOAc/Hexane) which showed that the starting material was consumed. The mixture was washed with H20 and saturated NaHC03 to remove excess methanesulfonyl chloride. The organic layer was concentrated under reduced pressure. The residue was dissolved in THF (350 mL) and added very slowly through an addition funnel to a refluxing solution of pyrrolidine (127.8, 1797 mmol) in THF (1650 mL) at 65°C. After the addition was completed, the reaction was allowed to stir at this temperature for 16 hours. The reaction was cooled to room temperature, then concentrated under reduced pressure to dryness . The residue was treated with H20 and extracted with EtOAc (2 x 1L) . The organic layers were combined, dried over Na2S04 and concentrated to dryness to afford a crude product 111 g (98%) . Example 3 Crystallization of the 5-Isopropyl-3- [2 (N- pyrrolidino) ethyl) ] -1-H-indole Succinic Acid Salt The crude material from Example 2 (111 g, 432 mmol) was dissolved in hot methanol (600 mL) and added to a hot solution of succinic acid (51.1 g, 432 mmol) in MeOH (250 mL) . After stirring for 5 hours, the white solid formed was filtered washed with ethanol to yield 111 g (70%) of 98% pure product.
EQUIVALENTS
While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.

Claims

CLAIMSWhat is claimed is:
1. A method of preparing a fused polycyclic nitrogen- containing heteroaromatic compound represented by the following structural formula:
Figure imgf000020_0001
or a physiologically acceptable salt thereof, wherein:
R1 is -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group ;
R2 is a substituted or unsubstituted 2-hydroxy-l- ethyl group; ring A is a substituted or unsubstituted aryl group; and ring B is substituted or unsubstituted at position two; said method comprising the step of reacting a substituted or unsubstituted 2 , 3-dihydrofuran with a salt of an aryl hydrazine, wherein the aryl hydrazine is represented by the structural formula
Figure imgf000021_0001
thereby forming said fused polycyclic nitrogen- containing heteroaromatic compound.
2 The method of Claim 1 further comprising the steps of: a) reacting the fused polycyclic nitrogen-containing compound with an activating agent, thereby forming a first intermediate; and b) reacting the first intermediate with a nucleophilic compound.
3. The method of Claim 2, wherein the activating agent is a thionyl halide or a sulfonyl chloride.
4. The method of Claim 3, wherein the activating agent is methanesulfonyl chloride.
5. The method of Claim 4, wherein the nucleophilic compound is an amine .
The method of Claim 5, wherein the amine is pyrrolidine .
The method of Claim 1, wherein the 2 , 3-dihydrofuran is unsubstituted and wherein the fused polycyclic nitrogen-containing heteroaromatic compound is represented by the following structural formula:
Figure imgf000022_0001
The method of Claim 1, wherein the aryl hydrazine is a substituted or unsubstituted phenyl hydrazine and, wherein the fused polycyclic nitrogen-containing heteroaromatic compound is represented by the following structural formula:
Figure imgf000022_0002
9. The method of Claim 8, wherein the 2 , 3-dihydrofuran is unsubstituted and, wherein the fused polycyclic nitrogen-containing heteroaromatic compound is represented by the following structural formula:
Figure imgf000023_0001
10. The method of Claim 9, wherein R1 is -H.
11. The method of Claim 9, wherein R1 is -CH3.
12. A method of preparing a fused polycyclic nitrogen- containing heteroaromatic compound represented by the following structural formula:
Figure imgf000023_0002
or a physiologically acceptable salt thereof, wherein:
R1 is -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group ;
R3, R4, R4', R5, and R5' are each, independently, -H, a aliphatic group, a substituted aliphatic group, an aryl group, a substituted aryl group, a halogen, a halogenated aliphatic group, nitro, nitrile, -C(0)NHR, -C(0)NRR, -NHC(0)R, -NRC(0)R, -OR, -SR, -S(0)R, or -S(0)2R;
R is an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group; and ring A is a substituted or unsubstituted aryl group ; said method comprising the step of reacting a salt derived from a substituted or unsubstituted aryl hydrazine represented by the following structural formula :
Figure imgf000024_0001
with a compound represented by the following structural formula:
Figure imgf000025_0001
thereby forming said fused polycyclic nitrogen- containing heteroaromatic compound.
PCT/US1999/010415 1998-05-15 1999-05-12 Method for making substituted indoles WO1999059970A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU39845/99A AU3984599A (en) 1998-05-15 1999-05-12 Method for making substituted indoles
JP2000549589A JP2002515485A (en) 1998-05-15 1999-05-12 Method for producing substituted indoles
CA002332766A CA2332766A1 (en) 1998-05-15 1999-05-12 Method for making substituted indoles
EP99922971A EP1077939A1 (en) 1998-05-15 1999-05-12 Method for making substituted indoles

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8563998P 1998-05-15 1998-05-15
US60/085,639 1998-05-15

Publications (1)

Publication Number Publication Date
WO1999059970A1 true WO1999059970A1 (en) 1999-11-25

Family

ID=22192971

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/010415 WO1999059970A1 (en) 1998-05-15 1999-05-12 Method for making substituted indoles

Country Status (6)

Country Link
US (1) US6133453A (en)
EP (1) EP1077939A1 (en)
JP (1) JP2002515485A (en)
AU (1) AU3984599A (en)
CA (1) CA2332766A1 (en)
WO (1) WO1999059970A1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2499987A1 (en) * 1981-02-19 1982-08-20 Kawaken Fine Chemicals Co PROCESS FOR THE PREPARATION OF O-INDOL-3-YL-ALKANOL COMPOUNDS
EP0500086A1 (en) * 1991-02-22 1992-08-26 Glaxo Group Limited Indole derivatives, their use as medicines and pharmaceutical compositions containing them
EP0675109A1 (en) * 1992-12-21 1995-10-04 Taisho Pharmaceutical Co. Ltd N-substituted indole derivative

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0126630B1 (en) * 1983-05-18 1987-09-16 Monash University The use of melatonin for the manufacture of a medicament
US4600723A (en) * 1983-05-18 1986-07-15 Monash University Method for minimizing disturbances in circadian rhythms of bodily performance and function
US4855305A (en) * 1987-03-23 1989-08-08 Applied Medical Research Compositions and methods of effecting contraception utilizing melatonin
US5093352A (en) * 1988-11-14 1992-03-03 Whitby Research, Inc. Antidepressant agents
US4945103A (en) * 1989-01-17 1990-07-31 Michael Cohen Method of treating pre-menstrual syndrome
JPH03218351A (en) * 1989-11-10 1991-09-25 Mitsui Toatsu Chem Inc Preparation of indoles
GB9013845D0 (en) * 1990-06-21 1990-08-15 Glaxo Group Ltd Process
ATE190490T1 (en) * 1990-09-28 2000-04-15 I F L O S A S Di Giorgio E Ald CONTRACEPTIVE AND MENSTRUAL CYCLE REGULATING PREPARATION WITH ONCOSTATIC PROPERTIES
DE4037004A1 (en) * 1990-11-21 1992-05-27 Bayer Ag METHOD FOR THE PRODUCTION OF INDOLES
US5242941A (en) * 1990-12-04 1993-09-07 State Of Oregon Methods of treating circadian rhythm disorders
US5403851A (en) * 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
TW455581B (en) * 1997-06-26 2001-09-21 Lilly Co Eli Process for preparing 4-substituted-1H-indole-3-glyoxamides
US5932743A (en) * 1997-08-21 1999-08-03 American Home Products Corporation Methods for the solid phase synthesis of substituted indole compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2499987A1 (en) * 1981-02-19 1982-08-20 Kawaken Fine Chemicals Co PROCESS FOR THE PREPARATION OF O-INDOL-3-YL-ALKANOL COMPOUNDS
EP0500086A1 (en) * 1991-02-22 1992-08-26 Glaxo Group Limited Indole derivatives, their use as medicines and pharmaceutical compositions containing them
EP0675109A1 (en) * 1992-12-21 1995-10-04 Taisho Pharmaceutical Co. Ltd N-substituted indole derivative

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 78, no. 7, 19 February 1973, Columbus, Ohio, US; abstract no. 43192s, GRANDBERG, I. I. ET AL.: "Indoles. XXXII. Synthesis of tryptophols." XP002113904 *
KHIM. GETEROTSIKL. SOEDIN., vol. 10, - 1972, pages 1366 - 1367 *

Also Published As

Publication number Publication date
CA2332766A1 (en) 1999-11-25
EP1077939A1 (en) 2001-02-28
JP2002515485A (en) 2002-05-28
US6133453A (en) 2000-10-17
AU3984599A (en) 1999-12-06

Similar Documents

Publication Publication Date Title
RU2544856C2 (en) NEW 2,3,4,5-TETRAHYDRO-1-PYRIDO[4,3-b]INDOLE DERIVATIVES AND METHODS FOR USING THEM
DE69132450T2 (en) Serotonin 5HT1A and 5HT1D agonists
JPH11512701A (en) Selective β ▲ 3 ▼ adrenergic agonist
CZ117293A3 (en) Novel pyrazole derivatives, process of their preparation and pharmaceutical preparations in which they are comprised
JP2008013556A (en) New naphthalene compound, method for producing the same and pharmacological composition containing the same
PT610134E (en) INDAZOLE AND BENZISOXAZOL INDOLE DERIVATIVES AS A 5-HT1-LIKE AQUATICS
FR2891829A1 (en) 4-AMINO-QUINAZOLINE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE THEREOF
CA2152902C (en) Selective ligands of receptors 5-ht1d-5ht1b derived from indole-piperazine useful as medicaments
KR900004385B1 (en) Carboxamide derivatives and preparing process thereof
FR2630328A1 (en) HISTAMINE DERIVATIVE, ITS PREPARATION AND ITS THERAPEUTIC APPLICATION
FR2574793A1 (en) INDOLE DERIVATIVE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, AND PROCESS FOR THEIR PREPARATION
ES2201111T3 (en) DERIVATIVES OF 3-AZA-BICYCLE (3,2,0) HEPTANE N-SUBSTITUTED AS NEUROLEPTICS.
US5319096A (en) (1H-indol-1-yl)-2-(amino) acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides, pharmaceutical composition and use
US4898863A (en) Heterocyclic carboxamides
EP0002978B1 (en) Thiazolidinedione-2,4 derivatives, their preparation and pharmaceutical applications
BG62349B2 (en) N-substituted derivatives of 3-azabicyclo [3.2.0] heptane as neuroleptics
US6133453A (en) Method for making substituted indoles
HUT61002A (en) Process for producing 2-aminopyrimdine-4-carboxamide derivatives and pharmaceutical compositions comprising such compounds
PL182810B1 (en) N-substituted derivatives of azabicycoheptane, method of obtaining them and their application
EP0625514B1 (en) 2-Amino-pyrazin-5-carboxamid derivatives, their preparation and their use in therapy
NO821725L (en) PROCEDURE FOR THE PREPARATION OF HETEROCYCLIC AMIDOXIM DERIVATIVES.
PT94298B (en) PROCESS FOR THE PREPARATION OF 4, 5, 5A, 6-TETRAHYDRO-3H-ISOXAZOLE (5,4,3-K1) ACRIDINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DK167922B1 (en) Quinaldineamide derivatives, a process for preparing them, and a pharmaceutical preparation which comprises such a derivative
KR100682702B1 (en) Novel phenylnaphthalene derivatives, method for production thereof and pharmaceutical compositions comprising the same
Mcdonald et al. Serotonin 5HT 1A agonistic method

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 39845/99

Country of ref document: AU

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 549589

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref document number: 2332766

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999922971

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999922971

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999922971

Country of ref document: EP